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Background: Community-acquired pneumonia (CAP) is a serious cause of morbidity among children in developed
countries. The real impact of 7-valent pneumococcal conjugate vaccine (PCV7) on pneumococcal pneumonia is difficult
to assess accurately.
Methods: Children aged ≤16 years with clinical and radiological pneumonia were enrolled in a multicenter prospective
study. Children aged ≤16 years admitted for a minor elective surgery was recruited as controls. Nasopharyngeal samples
for PCR serotyping of S. pneumoniae were obtained in both groups. Informations on age, gender, PCV7 vaccination
status, day care/school attendance, siblings, tobacco exposure were collected.
Results: In children with CAP (n=236), 54% of the nasopharyngeal swabs were PCR-positive for S. pneumoniae
compared to 32% in controls (n=105) (p=0.003). Serotype 19A was the most common pneumococcal serotype carried in
children with CAP (13%) and in controls (15%). Most common serotypes were non-vaccine types (39.4% for CAP and
47.1% for controls) and serotypes included only in PCV13 (32.3% for CAP and 23.5% for controls). There was no
significant difference in vaccine serotype distribution between the two groups. In fully vaccinated children with CAP, the
proportion of serotypes carried only in PCV13 was higher (51.4%) than in partially vaccinated or non vaccinated children
(27.6% and 28.6% respectively, p=0.037).
Conclusions: Two to 4 years following introduction of PCV7, predominant S. pneumoniae serotypes carried in children
with CAP were non PCV7 serotypes, and the 6 new serotypes included in PCV13 accounted for 51.4% of carried
serotypes in fully vaccinated children.
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Community-acquired pneumonia (CAP) is a serious cause
of morbidity among children in developed countries and
has a considerable impact on health care systems. In chil-
dren <5 years old, Streptococcus pneumoniae is considered
the most important bacterial pathogen causing pneumonia
with an incidence rate of 462 per 100,000 in Europe [1].
Introduction of the 7-valent pneumococcal conju-
gate vaccine (PCV7) at the beginning of this century
provided significant protection against invasive dis-
eases such as meningitis and septicemia. Vaccination
also allowed reduction in nasopharyngeal carriage of
vaccine-serotype pneumococci among vaccinated children,
but induced an increased carriage of nonvaccine serotypes
(serotype replacement) [2-6].
After PCV7 was added to universal immunization
programs, a reduction of 13% to 65% in the hospitalization
rate for pneumonia was noted in the United States [7],
Canada [8], England [9], and Italy [10]. However, the real
impact of this vaccine on pneumococcal pneumonia is
difficult to assess accurately. Identifying the cause of a
lower respiratory tract infection remains a challenge for a
number of reasons: adequate samples are difficult to obtain,
and differentiation between infection and colonization
cannot always be made. Michelow et al. [11] reported that
using a sophisticated armentarium of blood PCR, serology
and culture for 6 viruses and bacteria, a pathogen
could be detected in 79% of children with pneumonia.
In a recent study we performed in Switzerland, we showed
that S. pneumoniae was recovered in 45% of cases of all
pneumonia, and in 71% of pneumonia where a bacteria
was evidenced [12].
Serotype determination in pneumococcal pneumonia
derives mainly from blood or pleural fluid in children
with invasive pneumonia. However, most cases of pneu-
monia are not bacteremic [12], resulting in difficulty to
determine serotypes causing non invasive pneumonia. It
is commonly accepted that carriage of S. pneumoniae
precedes invasive disease and infections such as otitis
media and pneumonia [13-15]. Although the presence of
S. pneumoniae in the nasopharynx during pneumonia
does not prove its causative role, a pneumococcal dis-
ease is likely to be caused by the serotype present in the
nasopharynx. A recent Israeli study estimated pneumo-
coccal serotype-specific disease potential in pediatric
community-acquired alveolar pneumonia, by comparing
nasopharyngeal pneumococcal carriage during disease to
carriage in healthy children [16]. They concluded that
serotypes 1, 5, 7F, 9V, 14, 19A, and 22F have a higher
disease potential for childhood pneumonia than do
serotypes 6A, 6B, 23A, and 35B. However, this study
was performed before routine implementation of the
heptavalent pneumococcal vaccine. Monitoring the changes
in pneumococcal nasopharyngeal carriage is important andcan provide early, relevant information on the vaccine
effect, particularly concerning the identification of serotypes
that may substantially contribute to pneumococcal diseases
in the post-vaccine era. To our knowledge, there is no data
on the effect of PCV7 on nasopharyngeal pneumococcal
colonization among children with CAP in Switzerland,
where the primary vaccine series is administered during
infancy and the booster dose at 12–15 months of age.
The aim of this two year prospective study was to docu-
ment the rate of nasopharyngeal carriage of pneumococci
in Swiss children suffering from CAP, compared to healthy
children and to assess serotype distributions in CAP and
the potential impact of PCV13.
Methods
Setting
A multicenter prospective cohort study was conducted
in the Pediatric Emergency Department of 3 major
hospitals in Switzerland (Geneva, Lausanne and Sion)
from January 2008 to September 2010. PCV7 has been
available in the routine vaccination program since January
2006 in Switzerland. Around 70% of infants of 2years of
age were fully vaccinated (3 doses) with PCV-7 at the
time of the study [17]. PCV13 has not been licensed
in Switzerland before 2011.
Subjects studied
We postulated that populations with high rates of S.
pneumoniae carriage are particularly valuable for studying
the impact of vaccination programs. The study population
was defined to maximize the probability of detecting an
impact on carriage of pneumococcal serotypes.
Cases were defined as children aged ≥2 months and
≤16 years seen at the pediatric emergency room with
fever (>38C) and cough, tachypnea or respiratory dis-
tress, and abnormal lung infiltrates on Chest X-ray
(CXR). Children with previously diagnosed chronic
lung or heart diseases, immunodeficiency syndromes
and hospital-acquired pneumonia were excluded. The
pediatric radiologist assessed the CXR, unaware of the
interpretation of other investigators, nor of the clinical
diagnosis. Definitive cases were those confirmed by the
radiologist according to the WHO criteria [18]. Blood tests
including White blood cell (WBC), C-reactive protein
(CRP), Procalcitonin (PCT) were obtained.
To determine the differences in serotype-specific
carriage rates in CAP children versus healthy children, a
control group was enrolled during the same period.
Children aged ≥2 months and ≤16 years, admitted to
the pediatric surgery division for a minor elective surgery
(inguinal hernias, circumcision, hypospadias) were re-
cruited as controls. Children with any history of chronic
disease or lower respiratory tract infection within the past
3 weeks were excluded.
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day care/school attendance, siblings, tobacco exposure
was collected in both groups.
Children were considered to be fully vaccinated if they
had completed 3 doses of the PCV7 at 2, 4 and 12 months
per the routine Swiss childhood vaccination schedule.
Children were considered to be incompletely vaccinated if
they had started but not completed the 3 doses.
Ethical approval was obtained from the Research
Ethics Committees of the University Hospitals of
Geneva, University Hospital of Lausanne and Hospitals of
Valais. Informed consent was obtained from parents
of participating children before recruitment.
Laboratory methods
Nasopharyngeal samples for S. pneumoniae PCR serotyping
were obtained systematically in both groups with a flexible
dacron-tipped swab (eSwab, Copan Inc., Brescia, Italy),
which was introduced into the nostrils and advanced until
resistance was found. They were taken at the time of
admission and were frozen at −80C in Amies medium
in order to be subsequently analyzed. Detection and
identification of S. pneumoniae, was done using a
Streptococcus pneumoniae serotyping assay that genotypes
eight capsular genes in order to identify pneumococcal
serotypes. The assay was performed on the INFINITI
analyzer (Autogenomics, Carlsbad, CA) and consists
in five main steps: multiplex PCR for target genes
amplification, primer extension and labeling for specific
polymorphisms identification, microarray hybridization,
fluorescence reading and interpretation by expert system.
The combination of nucleotides typed is compared to a
database of sequences in order to identify the serotype of
the sample. The assay also detects autolysin (lytA),
pneumolysin (ply) and an internal control, which use the
M13 bacteriophage. In silico, this assay allowed the precise
identification of 52S. pneumoniae serotypes using a single
assay, including the serotypes covered by PCV13. Fifty
subtypes were sequenced verified [19]. The limit of
detection for serotyping was one hundred genome
equivalents and was consistent for all serotypes.
In the present study, the serotypes included in the
7-valent pneumococcal conjugate vaccine (4, 6B, 9V,
14, 18C, 19F, and 23F) are defined as PCV7 and the
serotypes included in addition to PCV7 in the 13-valent
vaccine (1, 3, 5, 6A, 7F and 19A) are defined as PCV13.
The other serotypes are defined as non vaccine type, or
not determined.
Statistical analysis
Population description was made through usual tools,
using proportions for categorical data; mean and
95% confidence interval (CI) on the mean. Normality
assumption was checked by quantile-quantile plotsand Shapiro-Wilks’ test. Host and environmental factors
were compared between children with and without CAP
using t-tests for continuous variables (age) and Pearson
Chi-square analyses for categorical variables (day-care
attendance, siblings, gender, PCV7 vaccination status).
Means and 95% confidence interval (CI) for age, CRP, PCT,
and WBC were expressed. Nasopharyngeal carriage of S.
pneumoniae was compared between children with and
without CAP using Pearson’s Chi-square analyses and
Student’s T test for quantitative data. S. pneumoniae
serotypes carried in CAP patients and healthy controls was
studied through multiple regression analysis, adjusting for
age, gender and PCV7 vaccination status to ensure the
comparability between the two groups. PCV7 vaccination
status in CAP patients and healthy controls as well as the
influence of PCV7 vaccination status on S. pneumoniae
carriage has been studied using a multivariate analysis
including age and gender as adjusting variables. A 2-tailed
cut-off of p<0.05 was considered a statistically significant
difference.
Data were analysed using the statistical analysis package
SPSS for Windows, version 15.0.
Results
Study population
During the study period, 236 patients with CAP and 105
control patients were enrolled.
General characteristics of the study cohort are described
in Table 1. The mean age of the CAP group was 4.7 yrs
(95% CI: 0.7-14) compared to 6.0yrs (95% CI: 1.2-15.1) for
the control group (p<0.001). The proportion of male
children was higher in the control group compared to
the CAP group (p=0.004). This is explained by the
high frequency of male-specific surgical procedures in
the control group (orchidopexia, inguinal hernias, circum-
cision, hypospadias). Among children with CAP, 26% had
received three doses of PCV7 compared with 13% in the
control patients (p=0.03). Incomplete vaccination was
found in 17 patients with CAP (7.9%) versus 3 control
patients (3.1%). One hundred forty two patients with CAP
(65.7%) were non vaccinated versus 81 control patients
(83.5%). The difference was not significant after adjustment
to age and gender (p=0.08; data not shown).
The presence of siblings, cigarette smoke exposure, and
day care/school attendance were similarly distributed
between children with and without a CAP.
Pneumococcal serotypes in the nasopharynx
In children with CAP, 54% of the nasopharyngeal
swabs were PCR-positive for S. pneumoniae compared
to 32% in healthy children (p=0.003; Table 1). Concerning
antibiotics use before ED visit, we have data for 122/127
patients with CAP. Only 20 patients received penicillin
before their ED visit. There was no significant difference
Table 1 Characteristics of the two groups of participants
Variables CAP (n=236) Healthy (n=105) p-value Adjusted p-values*
Mean (95% CI)
Age in years 4.7 (0.7-14) 6 (1.2-15.1) <0.001 -
Range (min-max) 0.24-15.3 0.20-16.3
CRP level mg/L 102 (9.6-315.2) NA - -
WBC count, cells *109/L 15.4 (4.5-35.6) NA - -
PCT 7.8 (0.06-57.8) NA - -
n (%)
Male 116/229 (51) 71/105 (68) 0.004 -
Fully vaccinated with PCV-7 57/216 (26) 13/97 (13) 0.004 -
Day care/school attendance 167/226 (74) 82/102 (80) 0.20 0.94
Number of siblings >1 152/223 (68) 76/103 (74) 0.30 0.56
Positive tobacco exposure 64/219 (29) 39/100 (39) 0.08 0.13
Nasopharyngeal SP_ PCR positive 127 (54) 34 (32) <0.0001 0.003
CAP indicates Community-acquired pneumonia; SP, Streptococcus pneumoniae; n, number; CRP, C reactive protein; WBC, white blood cell; PCT, Procalcitonin; NA,
not applicable.
* Chi-Square test adjusted by age, gender and PCV7 vaccination status (fully, partially or not).
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serotypes carried in children with CAP were 19A (13%), 6A
(9%), 6B (6%) and 7F (6%). For control patients, serotype
19A (15%) was the most common (Figure 1).
In both groups, PCV7 serotypes were infrequently
found (n=22, 13.7%). Most common serotypes were
non-vaccine types (39.4% for CAP and 47.1% for control
patients) and serotypes included only in PCV13 (32.3%
for CAP and 23.5% for control patients). S. pneumoniae
serotypes were not determined with the assay we used in0 5 10
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Figure 1 Nasopharyngeal carriage of S. pneumoniae individual seroty20.6% (n=7) of control patients and in 13.4%, (n=17) in
children with CAP. There was no significant difference
in vaccine serotype distribution between the two groups
(Table 2).
Figure 2 show that PCV13 would extend the potential
coverage to 47.3% of CAP and 32.3% of control patients.
For CAP cases, the addition of serotypes 19A, 6A and
7F included in PCV13 is important, because it would
add 13.4%, 9.4% and 6.3% to the overall serotype coverage
beyond PCV7.15 20 25
arriage of S. pneumoniae
Healthy controls
CAP
f
pes in children, CAP versus healthy controls.
Table 2 S. pneumoniae serotypes carried in CAP patients and healthy controls
CAP Healthy controls p-value Adjusted p-value*
(n=127) (n=34) (1) (2)
SEROTYPES 0.43 0.47 0.6
Included in PCV 7 19 (14.9%) 3 (8.8%)
Included only in PCV 13 (6 serotypes) 41 (32.3%) 8 (23.5%)
Non vaccine type 50 (39.4%) 16 (47.1%)
Not determined 17 (13.4%) 7 (20.6%)
* Chi-Square test adjusted by age, gender (1) and by age, gender and PCV7 vaccination status (2).
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As shown in Table 3, serotype distribution of S. pneumoniae
carried in CAP patients was significantly influenced by
PCV7 vaccination status (p=0.037). In fully vaccinated chil-
dren with CAP, the proportion of serotypes carried only in
PCV13 was higher (51.4%) than in the others groups: 27.6%
in patients who had received one or two doses and 28.6% in
non-vaccinated children. The other half of patients carried
nonvaccine types. Surprisingly, two fully vaccinated three
years old children with CAP carried PCV7 serotypes: 14
and 23F. For non-vaccinated children with CAP,
57.1% of them carried a non vaccine type and 14.3% a
PCV7 serotype (Table 3).
PCV7 vaccination status did not show any effect on
nasopharyngeal pneumococcal carriage between the two
groups (data shown in Table 4).
Discussion
Community-acquired pneumonia is one of the most
significant contributors to the morbidity and mortality
of pneumococcal disease. Detailed information on the
etiology of CAP is required for the initiation of an
appropriate treatment and for the evaluation of preventive
measures such as pneumococcal conjugate vaccines.
We have found that 2 to 4 years following introduction
of PCV7 in Switzerland, predominant S. pneumoniae
serotypes carried in children with CAP were non PCV70
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Figure 2 Cumulative potential serotype coverage of PCV7, PCV13 of sserotypes, and that the 6 new serotypes included in
PCV13 accounted for 51.4% of carried serotypes in fully
vaccinated children.
In our study, positive nasopharyngeal pneumococcal PCR
was found in half the children with CAP versus in only one
third of control patients. For control patients, these results
were similar to a recent American study where pneumococ-
cal carriage persisted in 30% of young children in the post-
PCV7 era [20]. As a rule, S. pneumoniae as the causative
serotype is found in the nasopharynx during non invasive
diseases like otitis media or pneumonia [13-15,21].
We found that pneumococcal serotypes 19A and 6A
were the most commonly carried serotypes in our study
population. These data are consistent with recent studies
from the US [20,22] and from Australia [23]. Other studies
showed that serotypes 6A, 6B and 19A were frequently
found during pneumonia [16,24]. The PROTEKT US study
[25] showed that the non vaccine serotypes 19A (19.0% of
all isolates) and 6A (7.8%) were among the most frequently
found serotypes in respiratory tract isolates from children
with non invasive diseases, 4 years after vaccine introduc-
tion. Serotypes 19A together with 7F are among the
major causes of pneumococcal empyema in the post-PCV7
era [26,27]. Serotype 19A is currently the major cause of
invasive pneumococcal disease [6,28-30], mastoiditis, and
refractory acute otitis media (AOM) in infants and children.
Moreover, it may be multidrug resistant [26,31,32].23F 1 3 5 6A 7F 19A
controls (n=34)
32.3
47.3
PCV13
erotypes in CAP patients and healthy controls.
Table 3 Serotype distribution of S. pneumoniae carried in CAP patients by PCV7 vaccination status
PCV7 vaccine status Total
SEROTYPES None 1 or 2 injections Fully
Included in PCV 7 9 (14.3%) 8 (27.6%) 2 (5.7%) 19 (15%)
Included only in PCV 13 (6 serotypes) 18 (28.6%) 8 (27.6%) 18 (51.4%) 44 (34.6%)
Non vaccine type 36 (57.1%) 13 (44.8%) 15 (42.9%) 64 (50.4%)
Total 63 (100%) 29 (100%) 35 (100%) 127 (100%)
Chi-Square=10.2 (p=0.037).
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riage of PCV7 serotypes was limited (10-15%) in both
children with and without CAP. Nevertheless, this is
higher than previously described in US studies showing
a reduction in carriage of PCV7 serotypes from 36% in
2001, to 3% 6 to 8 years after introduction of PCV7
[20,22] and in an Australian study 2 to 4 years after
introduction of PCV7 showing a result of 3% [23]. It
may be explained by the low vaccination coverage in our
study population compared to these countries [17]. In
our study, among the children with CAP, 26% had
received three doses of PCV7 compared with 13% of
the control patients.
In fully vaccinated children with CAP, the proportion
of non-PCV7 serotypes carried was predominant. In this
group, half of the serotypes were those included in the
new PCV13 vaccine and almost one half were non
PCV13 serotypes. The importance of non vaccine type
(neither PCV7 nor PCV13) existed likewise in non
vaccinated children with CAP. An important finding
of almost all trials concerning the conjugate pneumococcal
vaccine is not only a significant reduction in nasopharyn-
geal carriage of pneumococci serotypes included in PCV7
but also a concomitant increase in carriage of non-PCV7
serotypes, in 39% up to 79% of cases [33,34]. In recent
years, data showed the same phenomenon for invasive
diseases [6,35]. Marchese et al. [36] using blood PCR,
showed that more than 47% of Bacteremic pneumonia
cases in children less than 5 years old were due to
non-PCV7 serotypes. Concerning non invasive diseases,
Casey et al. [22] reported that non-PCV7 serotypes like
19A and 6A were among the most common causes of
pneumococcal otitis media in the post-PCV7 era. However,
care should be taken when assuming a causal relationshipTable 4 Influence of PCV7 vaccination status on S. pneumonia
Nasopharyngeal SP_PCR +
(n=151)
PCV7 Vaccination status
Fully vaccinated 40 (26.5%)
Partially vaccinated 13 (8.6%)
None 98 (64.9%
*Chi-Square test adjusted by age, gender.between PCV7 vaccination and an increase in 19A
diseases, since recent reports describe an increase in
19A even in countries without routine PCV7 vaccination
[37,38]. A French study [39], showed that 19A carriage was
the first leading non-vaccine serotype. It did not increase
significantly (between 8% and 10%) over a 5-year period
(2001-2006) and was comparable in both vaccinated and
non-vaccinated populations with acute otitis media.
In February 2010, a novel PCV13 was licensed for US
children aged 6weeks to 71months. PCV13 includes
serotypes 1, 3, 5, 6A, 7F, and 19A in addition to the
serotypes contained in PCV7. This should limit the
spread of serotype 19A by providing direct protection.
Our study showed that the 6 new serotypes of PCV13
would extend the coverage in 47% of CAP and in 32% of
control patients. In our population, the addition of sero-
types 19A, 6A and 7F included in PCV13 would add
13.4%, 9.4% and 6.3% to the overall serotype coverage
beyond PCV7. Shouval et al. [40] showed that PCV13
extended the coverage to 79% of acute otitis media and
67% of carriage groups versus 54% and 46% respectively,
with PCV7. The scenario for prevention of acute otitis
media and non bacteremic pneumonia is less clear than
in invasive diseases. Indeed, the differences in “invasive
capacity” among serotypes with regard to their ability to
ascend the Eustachian tube or overcome host defenses
of the respiratory tract appear to be small. However,
increased serotype coverage of PCV13 is expected to
have a substantial public health impact on infectious
diseases. Chuck AW et al. [41] developed a simulation
model for an entire population, providing vaccine to
children less than 2 years of age. With PCV 13-valent
vaccine introduction and a herd effect, pneumonia
cases would reduce from 373 per 100,000 persons withe carriage
Nasopharyngeal SP_PCR - p-value Adjusted
p-value*(n=162)
0.046 0.98
30 (18.5%)
7 (4.3%)
125 (77.2%)
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have an important role in the reduction of disease in both
vaccinated and unvaccinated people, through decrease in
the nasopharyngeal carriage of vaccine serotypes [42,43].
This study has several limitations. It revealed considerable
diversity in serotypes within pneumococci retrieved from
cases of CAP and control patients. As a consequence, many
serotypes were not present in sufficient numbers to furnish
statistical power to detect an association with carriage or
CAP. We cannot draw conclusions on how the not
determined nasopharyngeal serotypes might have impacted
the serotype distribution in our study. There are differences
in the distribution of risk factors between the two
groups of children, which may influence the comparison
between these groups. However, these factors were taken
into account in our statistical analyses.
Conclusion
In conclusion, although PCV7 has the potential to sub-
stantially decrease pneumococcal diseases, carriage and
spread, our results strongly suggest that PCV13 could
have a significant added benefit in reducing pneumococcal
pneumonia burden in Switzerland. Bacteriologic surveys
of community-acquired pneumonia remain necessary.
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